17
Participants
Start Date
December 28, 2021
Primary Completion Date
December 16, 2022
Study Completion Date
December 16, 2022
REPLAGAL
Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.
Hospital General Universitario de Alicante, Alicante
Hospital de Torrecárdenas, Almería
Hospital Universitario Vall d'Hebrón - PPDS, Barcelona
Charité - Universitätsklinikum, Berlin
Laiko General Hospital of Athens, Athens
Attikon University General Hospital, Athens
Onasseio Private Practise Hospital of Piraeus, Kallithea
Hospital Universitario La Paz, Madrid
Hospital Universitario Virgen del Rocio - PPDS, Seville
University Hospital of Ioannina, Ioannina
Hospital Quironsalud Zaragoza, Zaragoza
Papageorgiou General Hospital of Thessaloniki, Thessaloniki
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz
Vaasan Keskussairaala, Vaasa
SphinCS, Höchheim
University General Hospital of Heraklion, Heraklion
Akademiska Sjukhuset I Uppsala, Uppsala
Fachinternistische Gemeinschaftspraxis, Müllheim
Universitaetsklinikum Wuerzburg, Würzburg
M.A.G.I.C. Clinic Ltd. Metabolics and Genetics in Calgary, Calgary
Queen Elizabeth II Health Sciences Center, Halifax
Turun Yliopistollinen Keskussairaala, Turku
Szpital Uniwersytecki, Krakow
Narodowy Instytut Kardiologii im Prymasa Tysiaclecia Kardynala Stefana Wyszynskiego - Instytut Badaw, Warsaw
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw
Centro Hospitalar e Universitário de Coimbra EPE, Coimbra
Hospital Senhora da Oliveira - Guimaraes, E.P.E, Guimarães
Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisbon
Lead Sponsor
Shire
INDUSTRY